MedTrace Logo

A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD

NCT07333183 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2026-04-22

No results posted yet for this study

Summary

This is a Phase 2, open-label, multi-center clinical study to evaluate the safety and tolerability of inhaled mosliciguat in participants with pulmonary hypertension associated with interstitial lung disease (PH-ILD) on a background inhaled treprostinil.

Conditions

Interventions

DRUG

inhaled mosliciguat

Dose level 1, 2, or 3 for inhalation

DEVICE

Dry Powder Inhaler

Dry powder inhaler for mosliciguat delivery

Sponsors & Collaborators

  • Pulmovant, Inc.

    lead INDUSTRY

Principal Investigators

  • Ubaldo Martin, MD · Pulmovant, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-23
Primary Completion
2026-12-31
Completion
2028-01-31
FDA Drug
Yes
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07333183 on ClinicalTrials.gov